Approved Drug Label (PDF)
Boxed Warning
Removal of
Osteosarcoma Boxed Warning
4
Contraindications
Additions and/or
revisions underlined:
FORTEO
is contraindicated in patients with hypersensitivity to teriparatide or
to any of its excipients. Hypersensitivity reactions have included
angioedema and anaphylaxis [see Adverse
Reactions (6.3)].
5
Warnings and Precautions
5.1 Osteosarcoma
Additions and/or
revisions underlined:
An increase in the incidence of osteosarcoma (a malignant
bone tumor) was
observed in male and female rats treated with teriparatide. Osteosarcoma has been reported in patients
treated with FORTEO in the post marketing setting; however,
an increased risk of osteosarcoma has not been observed
in observational studies
in humans. There are limited data assessing the risk of osteosarcoma beyond 2 years of FORTEO
use [see Dosage and Administration (2.3),
Adverse Reactions
(6.3), and Nonclinical Toxicology (13.1)].
Avoid FORTEO use in patients with (these
patients are
at increased baseline risk of osteosarcoma):
Open epiphyses (pediatric and young adult patients) (FORTEO is not approved in pediatric
patients [see Use in Specific Populations (8.4)].
Metabolic bone diseases
other than osteoporosis, including
Paget’s disease
of the bone.
Bone metastases or a history of skeletal malignancies.
Prior external beam or implant
radiation therapy involving the skeleton.
5.2
Hypercalcemia and Cutaneous Calcification
Additions and/or
revisions underlined:
Hypercalcemia
FORTEO has not been studied in patients with pre-existing hypercalcemia.
FORTEO may cause hypercalcemia and may exacerbate hypercalcemia in
patients with pre-existing hypercalcemia [see
Adverse Reactions (6.1, 6.3)]. Avoid FORTEO in patients known to have an
underlying hypercalcemic disorder, such as primary hyperparathyroidism.
Risk of Cutaneous Calcification Including Calciphylaxis
Serious reports of calciphylaxis and worsening of previously stable
cutaneous calcification have been reported in the post- marketing setting in
patients taking FORTEO. Risk factors for development of calciphylaxis include
underlying auto- immune disease, kidney failure, and concomitant warfarin or
systemic corticosteroid use. Discontinue FORTEO in patients who develop
calciphylaxis or worsening of previously stable cutaneous calcification.
5.3 Risk of
Urolithiasis
Additions and/or
revisions underlined:
In clinical trials, the frequency of urolithiasis was similar in
patients treated with FORTEO and patients treated with placebo. However,
FORTEO has not been studied in patients with active urolithiasis. If FORTEO-treated
patients have pre-existing hypercalciuria or suspected/known active
urolithiasis, consider measuring urinary calcium excretion.
Consider the risks and benefits of use in patients with active or recent
urolithiasis because of the potential to exacerbate this condition.
5.4 Orthostatic
Hypotension
Additions and/or
revisions underlined:
FORTEO should be administered initially under circumstances in which the
patient can sit or lie down if symptoms of orthostatic hypotension occur. In
short-term clinical pharmacology studies of FORTEO in healthy volunteers,
transient episodes of symptomatic orthostatic hypotension were observed in 5%
of volunteers. Typically, these events began within 4 hours of
dosing and resolved (without treatment) within a few minutes to a few
hours …
5.5 Risk of Digoxin
Toxicity
Additions and/or
revisions underlined:
Hypercalcemia may predispose patients to digitalis toxicity because
FORTEO transiently increases serum calcium. Consider the potential onset of
signs and symptoms of digitalis toxicity when FORTEO is used in patients
receiving digoxin [see Drug Interactions
(7.1) and Clinical Pharmacology (12.3)].
6
Adverse Reactions
6.1 Clinical Trials
Experience
Additions and/or
revisions underlined:
… Men with Primary or Hypogonadal Osteoporosis and Postmenopausal
Women with Osteoporosis
Group(s) replaces patient(s)
Table
1: Percentage of Patients with Adverse Events Reported by at Least 2% of
FORTEO-Treated Patients and in More FORTEO-Treated Patients than
Placebo-Treated Patients from the Two Principal Osteoporosis Trials in Women
and Men Adverse Events are Shown Without Attribution of Causality
Laboratory
Findings
Serum Calcium — FORTEO
transiently increased serum calcium … different from pretreatment levels. In
clinical trials, the frequency of at least 1 episode of transient hypercalcemia
in the 4 to 6 hours after FORTEO administration was 11% of women and 6% of men
treated with FORTEO compared to 2% of women and 0% of the men treated with
placebo. The percentage of patients treated with FORTEO whose
transient hypercalcemia was verified on consecutive measurements was 3% of
women and 1% of men.
There
was no increase in
mortality in the FORTEO group compared to the active control group. The
incidence of serious adverse events was 21% in FORTEO patients and 18% in
active control patients …
Newly added
subsection:
6.2 Immunogenicity
As
with all peptides, there is potential for immunogenicity. The detection of
antibody formation is highly dependent on the sensitivity and specificity of
the assay. Additionally, the observed incidence of antibody (including
neutralizing antibody) positivity in an assay may be influenced by several
factors, including assay methodology, sample handling, timing of sample
collection, concomitant medications, and underlying disease. For these reasons,
comparison of the incidence of antibodies in the studies described below with
the incidence of antibodies in other studies or to other teriparatide products
may be misleading.
In
the clinical trial of postmenopausal women with osteoporosis [see Clinical Studies (14.1)],
antibodies that cross reacted with teriparatide were detected in 3% of women
(15/541) who received FORTEO. Generally, antibodies were first detected following 12 months of treatment and
diminished after withdrawal of therapy. There was no evidence of
hypersensitivity reactions among these patients. Antibody formation did not
appear to have effects on serum calcium, or on bone mineral density (BMD)
response.
6.3 Postmarketing
Experience
Additions and/or
revisions underlined:
Adverse
Reactions from Postmarketing Spontaneous Reports
The
following adverse reactions have been identified during postapproval use of
FORTEO …
…
Adverse Reactions from Observational Studies to Assess Incidence of
Osteosarcoma
Two
osteosarcoma surveillance safety studies (U.S. claims-based database studies)
were designed to obtain data on the incidence rate of osteosarcoma among
FORTEO-treated patients. In these two studies, three and zero osteosarcoma
cases were identified among 379,283 and 153,316 FORTEO users, respectively. The
study results suggest a similar risk for osteosarcoma between FORTEO users and
their comparators. However, the interpretation of the study results calls for
caution owing to the limitations of the data sources which do not allow for
complete measurement and control for confounders.
7
Drug Interactions
7.1 Digoxin
Additions and/or
revisions underlined:
Sporadic
case reports have suggested that hypercalcemia may predispose patients to digitalis
toxicity. FORTEO may transiently increase serum calcium. Consider the
potential onset of signs and symptoms of digitalis toxicity when FORTEO is used
in patients receiving digoxin [see
Warnings and Precaution (5.5) and Clinical Pharmacology (12.3)].
8
Use in Specific Populations
8.2 Lactation
Additions and/or
revisions underlined:
Risk
Summary
It
is not known whether teriparatide is excreted in human milk, affects human milk
production, or has effects on the breastfed infant. Avoid FORTEO use in
women who are breastfeeding.
8.4 Pediatric Use
Additions and/or
revisions underlined:
The
safety and effectiveness of FORTEO have not been established in
pediatric patients. Pediatric patients are at higher baseline
risk of osteosarcoma because of open epiphyses [see Warnings and Precautions (5.1)].
8.5 Geriatric Use
Additions and/or
revisions underlined:
Of
the patients who received FORTEO in the osteoporosis trial of 1637
postmenopausal women, 75% were 65 years of age and older and 23% were 75
years of age and older. Of the patients who received FORTEO in
the trial of 437 men with primary or hypogonadal osteoporosis, 39% were
65 years of age and over and 13% were 75 years of age and over. Of the 214
patients who received FORTEO in the glucocorticoid induced osteoporosis trial,
28% were 65 years of age and older and 9% were 75 years of age and older.
No overall differences in safety or effectiveness of FORTEO have been
observed between patients 65 years of age and older and younger adult
patients.
8.7 Renal
Impairment
Additions and/or
revisions underlined:
In
5 patients with severe renal impairment (CrCl<30 mL/minute), the AUC
and T1/2 of teriparatide were increased by 73% and 77%, respectively. Maximum
serum concentration of teriparatide was not increased. It is unknown whether
FORTEO alters the underlying metabolic bone disease seen in chronic renal
impairment [see Clinical Pharmacology
(12.3)].
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDE
Formatting has changed with extensive changes
throughout; please refer to label for complete information.
PATIENT COUNSELING INFORMATION
Additions and/or
revisions underlined:
Advise
the patient to read the FDA-approved patient labeling (Medication Guide and the
User Manual) before starting FORTEO and each time the prescription is renewed.
Failure to follow the instructions may result in inaccurate dosing.
Osteosarcoma
Patients
should be made aware that in rats, teriparatide caused an increase in the
incidence of osteosarcoma (a malignant bone tumor). Although cases of
osteosarcoma have been reported in patients using FORTEO no increased risk of
osteosarcoma was observed in adult humans treated with FORTEO [see Warnings and Precautions (5.1)].
Hypercalcemia
Instruct
patients taking FORTEO to contact a health care provider if they develop
persistent symptoms of hypercalcemia (e.g., nausea, vomiting, constipation,
lethargy, muscle weakness) [see
Warnings and Precautions (5.2)].
Orthostatic
Hypotension
When
initiating FORTEO treatment, instruct patients to be prepared to immediately
sit or lie down during or after administration in case they feel lightheaded or
have palpitations after the injection. Instruct patients to sit or lie down
until
the symptoms resolve. If symptoms persist or worsen, instruct patients to
consult a healthcare provider before continuing treatment [see Warnings and Precautions (5.4)].
Other
Osteoporosis Treatment Modalities
Patients
should be informed regarding the roles of supplemental calcium and/or vitamin
D.
Use
of the Prefilled Delivery Device (Pen)
Instruct patients and
caregivers who administer FORTEO on how to properly use the delivery device (refer to User Manual), to properly
dispose of needles, and not to share their prefilled delivery device
with other patients. Instruct patients and caregivers who administer FORTEO
that the contents of the delivery device should not be transferred to a
syringe.
Inform
patients that
each FORTEO delivery device can be used for up to 28 days. After the 28-day use
period, instruct patients to discard the FORTEO delivery device, even if
it still contains some unused solution. Instruct patients not to use FORTEO
after the expiration date printed on the delivery device and
packaging.
Approved Drug Label (PDF)
8
Use in Specific Populations
8.1 Pregnancy
(Pregnancy and
Lactation Labeling Rule (PLLR) conversion)
Risk Summary
There are no available data on FORTEO use in pregnant
women to evaluate
for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Consider discontinuing FORTEO when pregnancy is recognized.
In animal reproduction studies,
teriparatide increased skeletal
deviations and variations in mouse offspring at subcutaneous doses equivalent to more than 60 times the recommended 20 mcg human daily dose (based
on body surface area, mcg/m^2),
and produced mild growth retardation and reduced
motor activity in rat offspring at subcutaneous doses equivalent to more than 120 times the human dose.
The background risk of major birth defects
and miscarriage for the indicated population is unknown. The background risk
in the US general population of major birth defects
is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.
Data
Animal Data
In animal reproduction studies,
pregnant mice received teriparatide during organogenesis at subcutaneous doses equivalent to 8 to 267 times the human dose (based
on body surface area, mcg/m^2). At subcutaneous doses greater than or equal to 60 times the human
dose, the fetuses showed an increased incidence of skeletal deviations or variations (interrupted rib, extra vertebra or rib).
When pregnant rats received
teriparatide during
organogenesis at subcutaneous doses 16 to 540 times the human
dose, the fetuses showed no abnormal
findings.
In a perinatal/postnatal study in pregnant rats dosed subcutaneously from organogenesis through lactation, mild growth retardation was observed in female offspring
at doses greater than or equal to 120 times the human dose. Mild growth retardation in male offspring
and reduced motor activity in both male and female offspring
were observed at maternal doses of 540 times the human dose. There were no developmental or reproductive effects
in mice or rats at doses 8 or 16 times the human dose, respectively.
8.2 Lactation
(Pregnancy and
Lactation Labeling Rule (PLLR) conversion)
Risk Summary
It is not known whether
teriparatide is excreted in human milk, affects
human milk production, or has effects on the breastfed infant.
Because of the potential for osteosarcoma shown with teriparatide in animal
studies, advise
patients that breastfeeding is not recommended during treatment
with FORTEO.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDE
(addition of medication
guide; please refer to labeling for complete information)